Stock BAY BAYER AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bayer AG Warsaw S.E.

Equities

BAY

DE000BAY0017

Market Closed - Warsaw S.E.
Other stock markets
 11:55:46 2024-07-16 EDT 		5-day change 1st Jan Change
110.2 PLN -3.01% Intraday chart for Bayer AG -0.98% -23.49%
07-16 ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC CI
07-15 BAYER AG : UBS sticks Neutral ZD

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • With a P/E ratio at 10.98 for the current year and 7.75 for next year, earnings multiples are highly attractive compared with competitors.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BAYER AG Stock Bayer AG
-23.49% 28.29B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.53% 856B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.95% 631B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.66% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.06% 325B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.18% 297B
C+
ROCHE HOLDING AG Stock Roche Holding AG
+5.89% 234B
A+
NOVARTIS AG Stock Novartis AG
+16.53% 226B
B-
AMGEN INC. Stock Amgen Inc.
+15.67% 177B
C+
PFIZER, INC. Stock Pfizer, Inc.
+2.47% 165B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BAYN Stock
  4. BAY Stock
  5. Ratings Bayer AG